Bristol-Myers Squibb today reported, before Wall Street opened, detailed results from the Phase III CheckMate-227 clinical trial, testing Opdivo (nivolumab) low-dose 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg in patients with non-small cell lung cancer (NSCLC). The results show that the combination reduces cancer progression by 42%, despite the low dose.
Almost simultaneously, BMS’ competitor Merck & Co. has published results from the Phase III KEYNOTE-189 clinical trial, conducted in patients with NSCLC treated with Keytruda in combination with pemetrexed (Alimta) and chemotherapy. The trial has demonstrated that the combo helps reduce cancer progression by 51%.
Bristol-Myers Squibb’s and Merck & Co.’s shares soon reacted, but moving oppositely–BMS’s shares were down 5.5% as trading started, Merck & Co’s were up over 3%.
(Sources: Merck & Co, Bristol-Myers Squibb)